OrbiMed will join a $10-million financing round by closely-held NovellusDx led by IntraCure, a public life science holding company, and Pontifax, a leading Israeli life sciences VC, raising the size of the round to $12...

Oramed Pharmaceuticals (NASDAQ:ORMP) has received a $6.5-million milestone payment from Hefei Tianhui Incubator of Technologies (HTIT) under a December 2015 license and investment agreement. The payment follows Oramed’s...

The first 10 patients received treatment last week with Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant of buprenorphine, following FDA approval on May 26. ProbuphineProbuphine was developed using Titan’s long...

Avivagen (TSX-V:VIV) has provided results of four new trials of OxC-beta livestock as a feed additive for swine in the Philippines and Vietnam, and broiler poultry in the Philippines and Spain. In a new trial with the...

Dipexium Pharmaceuticals (NASDAQ:DPRX) and research collaborator, R. M. Alden Research Laboratory, presented data from two new Locilex microbiology studies at the American Society for Microbiology’s Microbe conference...

NBC News has become the latest media outlet to feature Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant for people addicted to heroin and prescription painkillers. As an implantable version of oral buprenorphine...

The peer-reviewed medical journal, Clinical Pharmacology in Drug Development, has published the combined results of two Phase 1 clinical trials by Juniper Pharmaceuticals (NASDAQ:JNP) that demonstrated the safety and...

Closely-held Braeburn Pharmaceuticals has presented data from the poster of the Phase 3 study of Probuphine, a six-month subdermal buprenorphine implant for the long-term maintenance treatment of opioid dependence, at...

Titan Pharmaceuticals (NASDAQ: TTNP) is presenting data today from four post hoc sensitivity analyses of the final Phase 3 trial of Probuphine at a poster session during The College on Problems of Drug Dependence 78th...

QLT (NASDAQ:QLTI; TSX:QLT) and Aegerion Pharmaceuticals (NASDAQ:AEGR) have entered into a definitive merger agreement, with the resulting company to be renamed, Novelion Therapeutics. Under the accord, each outstanding...

Titan Pharmaceuticals (NASDAQ:TTNP) has received a $15-million milestone payment from development and commercialization partner, Braeburn Pharmaceuticals, following FDA approval of Probuphine, the first six-month...

ARIAD Pharmaceuticals (NASDAQ:ARIA) has reported long-term follow-up data from its pivotal Phase 2 PACE clinical trial of Iclusig, its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or...

Closely-held Vital Connect, a leader in medical-grade wearable biosensor systems, has closed a term loan facility of $17.5-million with Perceptive Advisors, of which $10-million was funded at the initial closing today...

A Phase 2 clinical trial of Fibrocell Science’s (NASDAQ:FCSC) azficel-T for the treatment of vocal cord scarring resulting in chronic or severe dysphonia failed to meet its primary endpoints. Fibrocell intends to focus...

Anavex Life Sciences (NASDAQ:AVXL) has reported positive data for ANAVEX 2-73 in an exploratory study in a Fragile X syndrome model presented at the Gordon Research Conference for Fragile X and Autism-Related Disorder...

Ocular Therapeutix’s (NASDAQ:OCUL) results from its second Phase 3 clinical trial to evaluate the safety and efficacy of DEXTENZA, a bioresorbable intracanalicular depot, for the treatment of ocular itching associated...

ARIAD Pharmaceuticals (NASDAQ:ARIA) has reported updated clinical data for brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, from the pivotal ALTA trial in patients who had experienced disease...

Avivagen (TSX-V:VIV) has completed a private placement of brokered and non-brokered components, selling 60 million units for gross proceeds of $3.6-million. Each unit consists of one common share and one-half of a...

ARIAD Pharmaceuticals (NASDAQ:ARIA) has initiated a Phase 1/2 clinical trial of AP32788, an investigational tyrosine kinase inhibitor (TKI) designed as a targeted therapy for patients with non-small cell lung cancer...

ContraVir Pharmaceuticals (NASDAQ:CTRV) has entered into a definitive merger agreement with closely-held Ciclofilin Pharmaceuticals. Under the accord, ContraVir will acquire all of the outstanding equity interests in...

The merger of ContraVir Pharmaceuticals (NASDAQ:CTRV) with closely-held Ciclofilin Pharmaceuticals strengthens ContraVir’s position in the hepatitis B virus (HBV) space, according to a new report from Maxim Group...

The FDA has approved Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant, the first product for the long-term maintenance treatment of opioid dependence in clinically stable patients on 8 mg or less a day of oral...